Overview
Synthetic nucleotide analysis is a complex pursuit. Nucleic acid-based drugs combine the learnings from nature’s mechanisms with sophisticated technology. The diverse landscape of structural adaptions for bases and backbones has the potential to treat diseases with unprecedented specificity, but also increases the challenges for analyzing the synthetic oligonucelotide.
Move beyond boundaries for sequence confirmation, impurity ID, sizing and purity analysis and more with cutting-edge analytical solutions.
High-quality results for therapeutic oligos (ASO, siRNA, aptamers) and CRISPR/Cas9-related nucleic acids (gRNA, sgRNA, pegRNA) help you advance medicine.
Workflow
Impurity ID
Due to their stepwise synthesis, therapeutic oligonucleotides can contain a number of impurities with highly similar properties. These frequently extensively modified modalities show very complex fragmentation data that is difficult to interpret.
Take control of identity confirmation for your product and mitigate risks of impurities while keeping salt-adducts down. Don’t let base and backbone modifications hold you back. Determine the molecular weight, sequence and quanities of the active pharmaceutical ingredient (API) as well as impurities with customizable workflows.
Impurity ID
Solution
- Identfication and quantitation of impurities
- Robust, analytical flow setup
Impurity ID
Solution
- Highly sensitive impurity ID and quantitation with superior linear dynamic range (LDR)
- Meeting flexibility needs to perform a range of additional workflows
Featured resources
Remove barriers to the detection of impurities in your therapeutic oligonucleotide drugs. Explore how to achieve impurity ID with full sequence coverage for highly modified ASOs present at levels as low as 0.3%.
Imagine taking control of your CRISPR/Cas9 gene-editing systems by ensuring sgRNA integrity and purity. Be empowered to take on the challenge of future medicine development with accurate mass solutions that provide meaningful answers.
Workflow
Sizing and purity analysis
The latest gene-editing approaches require overcoming new analytical challenges. Confirmation of the size, integrity and purity of large synthetic guiding RNAs requires the highest data quality over a wide size range.
Move past analytical challenges with high separation quality, sensitivity and superior reproducibility. Reclaim your time with intuitive software and kit-based workflows that are compatible with compliant data systems.
Sizing and purity analysis
Solution
- High-quality resolution and sizing of RNAs and impurities
- Medium to large sample batches
Featured resources
Learn about an intuitive kit-based solution for the characterization of mRNA integrity and purity. Break through boundaries with workflows that provide the highest resolution for sgRNA and mRNA in a single analysis.
Set your own schedule for mRNA analyses by streamlining your CE data management with the Empower CDS.
Sizing and purity analysis
Solution
- High-quality resolution and sizing of RNAs and impurities
- Smaller sample sets
Workflow
Sizing and purity of large RNAs (pegRNA)
More sophisticated, chemically synthesized gRNAs are in development with the goal of increasing efficiency and specificity of CRISPR/Cas9 gene editing. One of these newly emerging classes is pegRNA with sizes ranging from around 120–250 nucleotides (nt).
The length and associated risk of secondary structure formation, however, pose challenges for the analytical assessment of its purity.
Move beyond these boundaries of CRISPR/Cas9 analysis and confirm size and purity for large pegRNA with confidence. Rely on high resolving power and repeatability to separate your products from impurities with similar properties.
Sizing and purity of large RNAs (pegRNA)
Solution
Workflow
Intact mass determination
Synthetic oligonucleotides —such as guide RNAs, sgRNAs and pegRNAs—are prone to a high number of impurities due to their stepwise chemical synthesis. Obtaining molecular weight information to confirm the identity of the main product and quantitation of related impurities is key for quality assessment prior to performing lengthy cell-based assays.
Take control of the purity of your products with high-quality, accurate mass data derived from intuitive solutions. Enable your team to gain key insights that are relevant for ensuring safety and efficacy.
Intact mass determination
Solution
- Straightforward molecular weight determination of sgRNAs and impurities
- Robust, analytical flow setup
Intact mass determination
Solution
- Straightforward molecular weight determination of sgRNAs and impurities
- Detection of low abundance impurities with superior linear dynamic range (LDR)
Featured resource
Imagine taking control of your CRISPR/Cas9 gene-editing systems by ensuring sgRNA integrity and purity. Be empowered to take on the challenge of future medicine development with accurate mass solutions that provide meani
Workflow
Conformation analysis
RNA structures can affect your particle formulations and the stability and efficacy of a final product. Gain greater control of structural prediction for your oligonucleotides of interest. Leverage solutions that gather empirical data without nucleotide or structural bias to enable better insights into RNA backbone flexibility from base-paired and unconstrained residues.
Conformation analysis
Solution
Workflow
Aptamer selection (CE-SELEX)
Selection of high-affinity target binders from pools of random aptamer sequences can be a challenging task. Apart from cumbersome processes taking weeks to months, the risk of enriching non-suitable binders and the loss of the strongest binders to surfaces are concerns linked to traditional approaches.
Take back your time with superior workflows to enrich the most promising aptamers for an efficient drug development process.
Aptamer selection (CE-SELEX)
Solution
Featured resources
Discover how to combine CE with systematic evolution of ligands by exponential enrichment (SELEX) to enable better and more efficient selection of your high-affinity DNA or RNA aptamers.
All resources
Take control of your API and related impurities with intuitive solutions. Discover how to confirm sequences of your product and achieve impurity ID for highly modified nucleic acid drugs.
Remove barriers to the detection of impurities in your therapeutic oligonucleotide drugs. Explore how to achieve impurity ID with full sequence coverage for highly modified ASOs present at levels as low as 0.3%.
Imagine taking control of your CRISPR/Cas9 gene-editing systems by ensuring sgRNA integrity and purity. Be empowered to take on the challenge of future medicine development with accurate mass solutions that provide meaningful answers.
Learn about an intuitive kit-based solution for the characterization of mRNA integrity and purity. Break through boundaries with workflows that provide the highest resolution for sgRNA and mRNA in a single analysis.
Set your own schedule for mRNA analyses by streamlining your CE data management with the Empower CDS.
Discover how to save time by streamlining your CE data management with the Empower CDS.
Create pathways for effective method development and learn how to achieve the highest quality data for RNA products with sizes ranging from 50–9,000 nucleotides and beyond.
Overcome secondary structure challenges presented by large-sized oligonucleotides for gene editing. Learn how to enable accurate and easy purity analysis of complex synthetic pegRNAs.
Discover how to combine CE with systematic evolution of ligands by exponential enrichment (SELEX) to enable better and more efficient selection of your high-affinity DNA or RNA aptamers.
Join professor Michael T. Bowser (Department of Chemistry, University of Minnesota) to learn how to take back your time for aptamer selection, while increasing the number of viable target sequences.